In vitro biological characterization and antiangiogenic effects of PD 166866, a selective inhibitor of the FGF-1 receptor tyrosine kinase

Journal of Pharmacology and Experimental Therapeutics

Volumn 286, Issue 1, 1998, Pages 569-577

  Panek, Robert L ^a   Lu, Gina H ^a   Dahring, Tawny K ^a   Batley, Brian L ^a   Connolly, Cleo ^a   Hamby, James M ^a   Brown, Kathryn J ^b  

^a PFIZER INC   (United States)

^b Australian National University   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

BASIC FIBROBLAST GROWTH FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR; FIBROBLAST GROWTH FACTOR 1; FIBROBLAST GROWTH FACTOR RECEPTOR; INSULIN RECEPTOR; MITOGEN ACTIVATED PROTEIN KINASE; PD 166866; PLATELET DERIVED GROWTH FACTOR B; PLATELET DERIVED GROWTH FACTOR RECEPTOR; PROTEIN KINASE C; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE KINASE INHIBITOR; UNCLASSIFIED DRUG;

ANGIOGENESIS; ANIMAL CELL; ARTICLE; ATHEROSCLEROTIC PLAQUE; AUTOPHOSPHORYLATION; CELL GROWTH; DRUG SYNTHESIS; HUMAN; HUMAN CELL; HUMAN TISSUE; NEOVASCULARIZATION (PATHOLOGY); NONHUMAN; PRIORITY JOURNAL; RAT; REGULATORY MECHANISM; VASCULAR SMOOTH MUSCLE;

3T3 CELLS; ANIMALS; FIBROBLAST GROWTH FACTORS; HUMANS; MICE; NEOVASCULARIZATION, PHYSIOLOGIC; PHOSPHORYLATION; PROTEIN-TYROSINE KINASES; PYRIMIDINES; RATS; RECEPTOR PROTEIN-TYROSINE KINASES; RECEPTOR, FIBROBLAST GROWTH FACTOR, TYPE 1; RECEPTORS, FIBROBLAST GROWTH FACTOR; UREA;

EID: 0031821631     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (36)

1. Bilder GE, Krawiec JA, Mcvety K, Gazit A, Gilon C, Lyall R, Zilberstein A, Levitzki A, Perrone MH and Schreiber AB (1991) Tyrphostins inhibit PDGF-induced DNA synthesis and associated early events in smooth muscle cells. Am J Physiol 260:C721-C730.
2. Blankley CJ, Boschelli DH, Doherty AM, Hamby JM, Klutchko S and Panek RL (1997) Pyrido[2,3-D]pyrimidines for inhibiting protein tyrosine kinase mediated cellular proliferation. United States patent No. 5,620,981.
3. Brogi E, Winkles JA, Underwood R, Clinton SK, Alberts GF and Libby P (1993) Distinct patterns of expression of fibroblast growth factors and their receptors in human atheroma and nonatherosclerotic arteries: Association of acidic FGF with plaque microvessels and macrophages. J Clin Invest 92:2408-2418.
4. Brown KJ, Maynes SF, Bezos A, Maguire DJ, Ford MD and Parish CR (1996) A novel in vitro assay for human angiogenesis. Lab Invest 75:539-555.
5. Buchdunger E, Zimmermann J, Mett H, Meyer T, Muller M, Regenass U and Lydon N (1995) Selective inhibition of the platelet-derived growth factor signal transduction pathway by a protein-tyrosine kinase inhibitor of the 2-phenylaminopyrimidine class. Proc Natl Acad Sci USA 92:2258-2262.
6. Burke TR (1992) Protein-tyrosine kinase inhibitors. Drugs Future 17:119-131.
7. Cadena DL and Gill GN (1992) Receptor tyrosine kinases. FASEB J 6:2332-2337.
8. Cleland WW (1979) Statistical analysis of enzyme kinetic data. Methods Enzymol 63:103-112.
9. Dolle RE, Dunn JA, Bobko M, Singh B, Kuster JE, Baizman E, Harris AL, Sawutz DG, Miller D, Wang S, Faltynek CR, Xie W, Sarup J, Bode DC, Pagani ED and Silver PJ (1994) 5,7-Dimethoxy-3-(4-pyridinyl)quinoline is a potent and selective inhibitor of human vascular β-type platelet-derived growth factor receptor tyrosine kinase. J Med Chem 37:2627-2629.
10. Dudley DT, Pang L, Decker SJ, Bridges AJ and Saltiel AR (1995) A synthetic inhibitor of the mitogen-activated protein kinase cascade. Proc Natl Acad Sci USA 92:7686-7689.
11. Fantl W, Johnson DE and Williams LT (1993) Signalling by receptor tyrosine kinases. Annu Rev Biochem 62:453-481.
12. Folkman J (1985) Toward an understanding of angiogenesis: Search and discovery. Perspect Biol Med 29:10-36.
13. Folkman J and Klagsbrun M (1987) Angiogenic factors. Science 235:442-447.
14. Friesel R and Maciag T (1995) Molecular mechanisms of angiogenesis: Fibroblast growth factor signal transduction. FASEB J 9:919-925.
15. Fry DW, Kraker AJ, Connors RC, Elliott WL, Nelson JM, Showalter HDH and Leopold WR (1994a) Strategies for the discovery of novel tyrosine kinase inhibitors with anticancer activity. Anti-Cancer Drug Design 9:331-351.
16. Fry DW, Kraker AJ, McMichael A, Ambroso LA, Nelson JM, Leopold WR, Connors RW and Bridges AJ (1994b) A specific inhibitor of the epidermal growth factor receptor tyrosine kinase. Science 265:1093-1095.
17. Jaye M, Schlessinger J and Dionne CA (1992) Fibroblast growth factor receptor tyrosine kinases: molecular analysis and signal transduction. Biochem Biophys Acta 1135:185-199.
18. Jensen RA, Beeler JF, Heidaran MA and LaRochelle WJ (1992) Characterization of baculovirus-expressed human α and β platelet-derived growth factor receptors. Biochemistry 31:10887-10892.
19. Klagsbrun M and D'Amore P (1991) Regulators of angiogenesis. Annu Rev Physiol 53:217-239.
20. Leatherbarrow RJ (1992) GraFit User's Guide, Version 3.0. Erithacus Software Ltd., Staines, UK.
21. Libby P, Schwartz D, Brogi E, Tanaka H and Clinton SK (1992) A cascade model for restenosis: A special case of atherosclerosis progression. Circulation 86:47-52.
22. Lyall RM, Zilberstein A, Gazit A, Gilon C, Levitzki A and Schlessinger J (1989) Tyrphostins inhibit epidermal growth factor (EGF)-receptor tyrosine kinase activity in living cells and EGF-stimulated cell proliferation. J Biol Chem 264:14503-14509.
23. Mohammadi M, Dikic I, Sorokin A, Burgess WH, Jaye M and Schlessinger J (1996) Identification of six novel autophosphorylation sites on fibroblast growth factor receptor 1 and elucidation of their importance in receptor activation and signal transduction. Mol Cell Biol 16:977-989.
24. Mohammadi M, McMahon G, Sun L, Tang C, Hirth P, Yeh B, Hubbard S and Schlessinger J (1997) Structures of the tyrosine kinase domain of fibroblast growth factor receptor in complex with inhibitors. Science 276:955-960.
25. Onoda T, Ishiki K, Takeuchi T, Tatsuta K and Umezawa K (1990) Inhibition of tyrosine kinase and epidermal growth factor receptor internalization by lavendustin: A methyl ester in cultured A431 cells. Drugs Expt Clin Res 16:249-253.
26. Panayotou G and Waterfield MD (1993) The assembly of signaling complexes by receptor tyrosine kinases. Bioessays 15:171-177.
27. Panek RL, Lu G, Klutchko SR, Batley BL, Dahring TK, Hamby JM, Hallak H, Doherty AM and Keiser J (1997) In vitro pharmacological characterization of PD 166285, a new nanomolar potent and broadly active protein tyrosine kinase inhibitor. J Pharmacol Exp Ther 283:1433-1444.
28. Ross R (1971) The smooth muscle cell. II. Growth of smooth muscle in culture and formation of elastic fibers. J Cell Biol 50:172-186.
29. Sawutz DG, Bode DC, Briggs GM, Reid JR, Canniff P, Caldwell L, Faltynek CR, Miller D, Dunn JA, deGaravilla L, Guiles JW, Weigelt C, Michne W, Treasurywala AM and Silver PJ (1996) In vitro characterization of a novel series of platelet derived growth factor receptor tyrosine kinase inhibitors. Biochem Pharmacol 51:1631-1638.
30. Thompson AM, Fry DW, Kraker AJ and Denny WA (1994) Tyrosine kinase inhibitors. 2. Synthesis of 2,2′-dithiobis(1H-indole-3-alkanmides) and investigation of their inhibitory activity against epidermal growth factor receptor and pp60v-src protein tyrosine kinases. J Med Chem 37:598-608.
31. Traxler P and Lydon N (1995) Recent advances in protein tyrosine kinase inhibitors. Drugs Future 20:1261-1274.
32. Trinks U, Buchdunger E and Furet P (1994) Dianilinopthalimides: potent and selective, ATP competitive inhibitors of the EGF-receptor protein tyrosine kinase. J Med Chem 37:1015-1027.
33. Ullrich A and Schlessinger J (1990) Signal transduction by receptors with tyrosine kinase activity. Cell 61:203-212.
34. Villaschi S and Nicosia RF (1993) Angiogenic role of endogenous basic fibroblast growth factor released by rat aorta after injury. Am J Pathol 143:181-190.
35. Ward WHJ, Cook PN, Slater AM, Davies H, Holdgate GA and Green LR (1994) Epidermal growth factor receptor tyrosine kinase: Investigation of catalytic mechanism, structure-based searching and discovery of a potent inhibitor. Biochem Pharmacol 48:659-666.
36. Zimmermann J, Buchdunger E, Mett H, Meyer T, Lydon NB and Traxler P (1996) Phenylamino-pyrimidine (PAP)-derivatives: A new class of potent and highly selective PDGF-receptor autophosphorylation inhibitors. Bioorg Med Chem Lett 6:1221-1226.